🚨 Watchlist Update: HAWK — Buy Level Triggered
HawkEye 360, Inc. (NYSE: HAWK) from our Top 10 Breakout Watchlist has broken out of a falling wedge pattern and crossed our buy level of $19.00, touching an intraday high of $19.28 before pulling back to close at $18.08. A decisive close above $19.00 would confirm the breakout.
Bottom line: HAWK has crossed its buy level intraday — watch for a close above $19.00 to confirm the move, then use trailing stops to lock in early gains and let the winner run. And now, on to today’s featured setup…
We flagged Insmed Incorporated (NASDAQ: INSM) in our breakout watchlist back in September — and the stock has since broken out of an eight-month falling wedge on a +20.58% single-session surge and looks headed even higher.
As we’ll get to just ahead, the combination of reports that a pharmaceutical giant is weighing a buyout, a blockbuster new drug launch that keeps beating expectations, and a fresh technical breakout makes INSM one of the more interesting setups on the board. Here’s what’s going on…
The Themes Behind the Move
Insmed is a Bridgewater, New Jersey-based biopharmaceutical company, founded in 1988, that develops and sells therapies for serious and rare diseases in the U.S., Europe, Japan, and beyond — led by Brinsupri (brensocatib), a once-daily pill for the chronic lung disease bronchiectasis, and Arikayce, an inhaled antibiotic for a hard-to-treat lung infection. Its pipeline also includes TPIP, an inhaled treatment for high blood pressure in the lungs, along with early-stage gene therapy programs for Duchenne muscular dystrophy and ALS.
In plain English, Insmed is a lung-disease specialist that has just made the leap from a one-product company to a fast-growing commercial story. Bronchiectasis is a condition in which the lungs’ airways become permanently widened and scarred, trapping mucus and leading to repeated flare-ups and infections — and Brinsupri is the first medicine approved specifically to treat its non-cystic fibrosis form. Its business hinges on how quickly Brinsupri keeps growing, whether Arikayce wins approval for a broader group of patients, whether TPIP succeeds in late-stage trials — and, as of this week, whether a big pharmaceutical buyer steps in.
INSM’s latest move reflects a powerful confluence of developments — strategic, commercial, and regulatory — that have come together in rapid succession to fundamentally reframe the company’s near-term growth trajectory.
| Theme / Catalyst | What Happened | Why Traders Care |
|---|---|---|
| Sanofi takeover interest | On November 19, 2026, Reuters reported, citing Bloomberg News, that French drugmaker Sanofi is working with advisers and evaluating an acquisition of Insmed. No offer, price, or definitive negotiations have been confirmed, and both companies declined to comment. INSM closed at $144.46 (+20.58%) as the market priced in takeover optionality. Separately, former Sanofi CEO Paul Hudson joined Insmed’s board in October, before the report — an interesting connection, though not evidence of deal talks. | Strategically, Brinsupri and TPIP could help Sanofi replace growth it will eventually lose as its blockbuster eczema and asthma drug Dupixent approaches its patent cliff — the point when a drug’s exclusivity ends and cheaper competitors can enter. Any transaction would likely rank among the pharmaceutical sector’s largest recent acquisitions. Even unconfirmed, the report spotlights how strategically valuable Insmed’s assets have become — though it also creates a binary downside path if the interest fades. |
| Brinsupri launch beats expectations + Japan expansion | Brinsupri generated $400.1 million in Q3 2026 (+29% sequentially), per Insmed’s Q3 results, and surpassed $1 billion in cumulative revenue during its first four full commercial quarters. Management raised FY2026 Brinsupri guidance to $1.35–$1.40 billion, lifting the bottom of the range by $100 million. Overseas, Japan approved Brinsupri in August, and Insmed launched it there on October 19 — the first therapy specifically approved for non-cystic fibrosis bronchiectasis in Japan. | This is the strongest element of the standalone thesis: Insmed is no longer valued solely on clinical projections — it now has a rapidly scaling commercial product. Management estimates Brinsupri could eventually exceed $7 billion in peak annual sales (a company forecast, not guaranteed revenue). Japan adds a second sizeable, underpenetrated market, though it contributed little to Q3 and still needs to prove its value in 2027 results. |
| Sector tailwinds | Large pharmaceutical companies are confronting a wave of patent expirations later this decade, and commercial-stage specialty biotechs with differentiated products remain prime acquisition targets. Insmed offers an unusual combination: an established respiratory franchise, an exceptionally strong new launch, and multiple late-stage pipeline opportunities. | That scarcity helps explain Sanofi’s reported interest — and it means Insmed’s strategic value doesn’t hinge on a single bidder. The counterpoint: a $30 billion-plus equity value materially limits the number of credible buyers, and financing a substantial premium could be difficult even for a large drugmaker. |
| Fundamentals snapshot | Insmed’s Q3 2026 revenue reached $524.4 million (+268% YoY), including $124.4 million from Arikayce (+9% YoY). The GAAP net loss narrowed to $100.3 million ($0.46 per share) from $370 million ($1.75 per share) a year earlier, and product gross margin is approximately 85%. FY2026 Arikayce guidance stands at $460–$470 million. The company held roughly $1.1 billion in cash and marketable securities at September 30, against about $1.5 billion in long-term debt, and management continues to target cash-flow positivity in 2027 without additional capital. | Losses are shrinking fast as revenue scales — Q3’s net loss was less than a third of the prior-year figure — and an ~85% product margin means each additional dollar of Brinsupri sales carries heavily toward the bottom line. At a roughly $31–$32 billion market cap, INSM trades near 17x guided FY2026 product revenue: demanding, but partly supported by Brinsupri’s growth rate and the company’s high margins. |
| Analyst coverage | Among the 17 analysts offering 12-month price targets tracked by TipRanks over the past three months, the average target sits at $191.67, with a high of $220.00 and a low of $158.00 — implying roughly 33% upside on average and about 52% upside at the top end from the latest close of $144.46. H.C. Wainwright initiated at Buy with the Street-high $220 target on November 4, Morgan Stanley reiterated Overweight at $213, Barclays holds Overweight at $207, and RBC Capital Markets reiterated Outperform at $195. Mizuho reiterated Buy at $158 on November 19, the day of the report. | Coverage is overwhelmingly constructive, with roughly 23 Buy or Strong Buy recommendations against very few neutral or negative ratings across the major aggregators. The average target lands right between our two price targets, and post-report analyst commentary floating possible takeout values around $170–$210 brackets the same zone. One caveat: many targets predate the Sanofi report and aren’t acquisition bids, so they’re best read as a vote of confidence in the standalone business. |
| Market conviction signal | The breakout came on 14.41M shares, one of the heaviest volume prints of the year. Options activity showed a strong bullish skew, per OptionsBell: 7,564 calls traded, roughly 85% above normal call volume, with a 0.22 put/call volume ratio — about one bearish put for every four to five bullish calls. Approximately $2.65 million in premium flowed into January 15, 2027 $160, $170, and $180 calls, led by about $1.99 million at the $160 strike. Reported short interest of roughly 6.2%–6.6% of float likely added fuel through short covering. | The strongest verified signal is the exceptional price-and-volume response to the takeover report. The call buying supports bullish interest, though without trade-side detail it can’t be cleanly labeled pure “smart-money” accumulation — some contracts could be spreads or hedges. Notably, those January calls expire 13 days before the FDA’s Arikayce decision, making them more consistent with takeover or news speculation than a bet on the FDA ruling itself. |
| Upcoming triggers | Traders are watching a planned Brinsupri branded advertising campaign in late November, Insmed’s presentation at the Evercore Healthcare Conference on December 1, a targeted Japanese filing for expanded Arikayce use by year-end, and the FDA’s decision on Arikayce’s expanded-use application — which was granted Priority Review, the FDA’s faster review track — due by January 28, 2027, with no advisory committee meeting currently planned. Also on deck: Q4/FY2026 results and the first 2027 outlook around February 2027 (date estimated), and a planned Phase 3 TPIP study in idiopathic pulmonary fibrosis (a progressive lung-scarring disease) in 1H 2027, building on its global Phase 3 PALM program. | A staggered set of catalysts — each capable of independently moving the stock into early 2027. An Arikayce approval could broaden the drug beyond its current hard-to-treat patient group and support management’s expectation of $1 billion+ in peak sales, while TPIP’s projected $6 billion-plus opportunity hinges on late-stage results. The most important trigger, however, remains unscheduled: confirmation, denial, or abandonment of Sanofi’s reported interest. |
If needed, swipe or scroll sideways to view the full table.
Put it all together, and INSM is looking less like a one-day takeover-rumor pop and more like a commercially executing respiratory franchise — with a blockbuster launch still scaling, a second major market now open, an FDA decision on deck, and a potential buyer reportedly circling.
The story is getting stronger, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.
Bullish Technical Signals
#1 Falling Wedge Pattern Breakout: Since its spring highs, INSM has spent roughly eight months forming a falling wedge on the daily chart (marked in purple). Two downward-sloping trendlines have been converging as each selloff carried less force than the one before. The late-October low near $93 held just above the June trough near $91. Price kept making new lows, but it was making them more slowly, which is the defining feature of the pattern. Thursday’s session ended the pattern decisively. INSM opened at $119.50, right at the wedge’s upper rail, and closed at $144.46, a +20.58% single-session gain on 14.41M shares, one of the heaviest volume prints of the year. A breakout of this size on expanding volume shows more than fading selling pressure: buyers took in the overhead supply the wedge had been capping. One nuance is worth flagging. The candle reached $149.07 intraday before giving some ground back. That upper wick shows sellers are still defending the $146–$149 zone, a congestion area from March–April, and it explains why the breakout entry is set above $146.00.
INSM – Daily Chart
#2 Price Above 50-Day and 200-Day SMAs: INSM now trades above both its 50-day SMA ($110.86) and its 200-day SMA ($122.61). The reclaim of the 200-day matters most. That average had been converging with the wedge’s upper rail through November, so Thursday’s candle cleared both ceilings at once. This is a trend-repair setup rather than an established uptrend: the 50-day still sits below the 200-day, and the 200-day is still sloping lower. What has changed is that the 50-day has bottomed and is curling higher. If that continues, the stage is set for a golden cross, the next confirmation to watch. The single-day surge has also left price extended, about 18% above the 200-day and about 30% above the 50-day. That is why the dual-entry structure fits: a pullback toward $137.00, the August swing high, would be a test of former resistance as new support rather than a break in the thesis. Below that, the averages form a tiered support shelf at about $122.6 (the 200-day and the breakout rail) and then about $111 (the 50-day).
#3 Bullish ADX and DI: The directional read is lopsided. +DI (48.66) has jumped above –DI (11.33), a spread of more than 37 points that puts directional control firmly with buyers. The more telling detail is the ADX line itself. During the October selloff, ADX peaked well above 50 while –DI was dominant, which reflected a strong bearish trend. It then unwound steadily as that selling ran its course. ADX (23.62) has now turned higher from that reset and sits between the two DI lines, with +DI firmly in the lead this time. The trend gaining strength is the bullish one. Because ADX is still below the 25 threshold, the new trend is in its early innings with room to build, not late and stretched. A push through 25 would confirm it has moved from forming to established.
#4 Bullish Aroon: The Aroon indicator shows a clean bullish configuration. Aroon Up (orange) is at 100%, while Aroon Down (blue) has slipped to 21.43%. Aroon Up at its ceiling means INSM has just set a fresh 14-day high, which fits Thursday’s breakout. Aroon Down near 21% means the last 14-day low is now about eleven sessions back and fading from the lookback window. Aroon Up has stayed above 70 for most of November, so this is not a one-day spike. It reflects a run of consistently higher highs that started before the breakout. Stacked against the ADX read, the two indicators agree: Aroon shows buyers setting the new extremes, and ADX shows the force behind those moves building.
#5 Symmetrical Triangle Breakout with Price Above 50-Week and 200-Week SMAs: The weekly chart puts the daily wedge in a larger frame. INSM’s 2024–2025 advance took the stock from the $20s to a peak above $200 in late 2025. Since then, price has formed a year-long symmetrical triangle (marked in pink): lower highs falling from that peak, higher lows rising from the spring-2025 base. Symmetrical triangles compress volatility and usually resolve in the direction of the prior trend, and here the prior trend is a multi-year uptrend. This week’s candle (so far +19.23%) has broken through the upper trendline and reclaimed the 50-week SMA ($130.48). That average had capped price since spring 2026, including the August rally that stalled below it. The 200-week SMA ($78.94) is still rising steeply beneath the 50-week, so the long-term golden alignment never broke during the consolidation. The daily wedge is effectively the lower-timeframe view of the triangle’s final leg, so both patterns breaking in the same week is real multi-timeframe confluence. One caveat: the weekly candle is not final until Friday’s close. A weekly close above the upper rail, and ideally above $130.48, would lock in the signal.
INSM – Weekly Chart
#6 Bullish MACD: On the weekly chart, the MACD line (–1.21) is above its signal line (–4.44), and the histogram (+3.23) is green and widening. The context makes this reading meaningful. Weekly MACD fell deep into negative territory during the mid-2026 decline, near –20. It has since climbed back almost to zero, and this crossover is firing just below the zero line rather than in a deeply negative zone. Crossovers near the zero line are higher quality because the momentum hole has largely been filled and the indicator is close to turning positive. The expanding histogram shows the gap between short-term and long-term momentum is still widening. The next confirmation is a MACD cross above zero, which would mean the 12-week EMA has reclaimed the 26-week EMA outright.
#7 Bullish Stochastic: On the weekly stochastic, %K (91.83) has crossed above %D (68.90), and the speed of the turn stands out. As recently as late October, both lines were pinned in single digits, deep in oversold territory. %K has since climbed about 85 points in roughly four weeks. A crossover that starts from an oversold base is one of the higher-conviction signals this oscillator gives, and on the weekly timeframe it points to a lasting shift in momentum rather than a short bounce. The tension is that %K is already above 80, in overbought territory, while %D still has room to rise. Overbought readings can persist for weeks in strong trends, so this is not a reason to step aside. It does reinforce the dual-entry logic: the $137.00 pullback entry offers a better risk profile than chasing a near-vertical weekly candle.
Risks to Consider
Even strong setups can fail, especially in an event-driven biotech like Insmed. A few things could knock the stock off course:
- A breakdown back inside the falling wedge on heavy volume — especially a close below the ~$122.60 zone where the 200-day SMA and the broken wedge rail converge — would invalidate the breakout thesis
- Negative company-specific news, broader market weakness, or regulatory changes across the biotech sector could trigger a sell-off
- No-deal risk — the November 19 gain is substantially event-driven, and if Sanofi declines to proceed, the stock could surrender part or all of the takeover premium, with the ~$119.80 November 18 close the cleanest unaffected-price reference. A deal potentially worth $35–$40 billion including a premium would also be large relative to Sanofi’s existing debt, and Insmed may prefer to remain independent
- Premium valuation — at roughly 17x guided FY2026 product revenue, INSM leaves little tolerance for slowing prescriptions, weaker patient persistence, or reimbursement difficulties
- Ongoing losses and debt — Insmed remains unprofitable, posting a Q3 GAAP net loss of $100.3 million while spending heavily on commercialization and clinical development, and it carries about $1.5 billion in long-term debt against roughly $1.1 billion in cash; hitting its 2027 cash-flow target requires continued execution
- Clinical and regulatory risk — Priority Review does not guarantee Arikayce approval on January 28, 2027, TPIP’s multi-billion-dollar value still depends on pivotal studies, and brensocatib previously failed in chronic rhinosinusitis, a reminder that success in bronchiectasis doesn’t automatically carry over to every indication
- Insider selling — a November 19 Form 144 disclosed a proposed sale of approximately 101,100 shares (about $14.7 million) by an Insmed officer under a pre-scheduled 10b5-1 trading plan adopted in May 2026; it’s routine and only a notice of a proposed sale, but it could weigh on sentiment
- Competition and policy — competing DPP1 inhibitors (drugs in the same class as Brinsupri), drug-pricing scrutiny, and future Medicare price-negotiation pressure under the Inflation Reduction Act could affect Brinsupri’s long-term economics
The Bottom Line
INSM is breaking out of an eight-month falling wedge on the daily chart while also clearing a year-long symmetrical triangle on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.
The fundamental story underneath the chart is just as strong: reported takeover interest from Sanofi, a $1 billion+ blockbuster launch in just four quarters, and a 268% jump in quarterly revenue.
Combine that with multiple catalysts staggered through the rest of 2026 and into 2027 — the Evercore Healthcare Conference on December 1, a targeted Japanese filing for expanded Arikayce use by year-end, the FDA’s Arikayce decision on January 28, 2027, and Q4 results with the first 2027 outlook around February — and INSM looks like one of the more compelling risk-reward setups on the board right now.
If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our two entry options — one on the breakout, one on a pullback — both price targets that imply 23%–46% potential upside, and the stop-losses we’re using to manage the downside.
Recommended Trade Setup
Because INSM is extended after a 20% single-session surge on takeover headlines, we’re laying out two ways to play it: a breakout entry for traders who want confirmation that the stock can clear the $146–$149 congestion zone, and a pullback entry — which offers the better risk profile — for those willing to wait for a retest of the $137.00 August swing high as new support.
Case 1: On Breakout
| Item | Detail |
|---|---|
| Buy Level | Above approximately $146.00 |
| Price Target 1 | $180.00 — Potential upside: 23% |
| Price Target 2 | $200.00 — Potential upside: 37% |
| Timeframe | Next 3–6 months |
| Stop-Loss | $128.00 on a closing basis |
| Trade Invalidation | Void if price hits stop-loss before entry triggers |
If needed, swipe or scroll sideways to view the full table.
For a risk of approximately $18.00 per share, the target rewards are about $34.00 and $54.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.
Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If INSM drops to or below the $128.00 stop-loss before the $146.00 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry.
Case 2: On Pullback
| Item | Detail |
|---|---|
| Buy Level | On pullback to approximately $137.00 |
| Price Target 1 | $180.00 — Potential upside: 31% |
| Price Target 2 | $200.00 — Potential upside: 46% |
| Timeframe | Next 3–6 months |
| Stop-Loss | $116.00 on a closing basis |
If needed, swipe or scroll sideways to view the full table.
For a risk of approximately $21.00 per share, the target rewards are about $43.00 and $63.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.
Happy Trading!
Tara and Greg
🥈 Almost Made the Cut
Today’s featured trade, Insmed Incorporated (NASDAQ: INSM), was our top pick of several breakout candidates we evaluated. The following two stocks were strong candidates that made it to the final round — they came up just short of the top spot, but remain on our watchlist and could be featured soon:
Allegiant Travel Company (NASDAQ: ALGT) — The leisure-focused airline is emerging as a cleaner, larger operator after closing its Sun Country acquisition, with a strong Q3 beat, a 340-basis-point pro forma margin improvement, raised Q4 guidance, and an extended Bank of America co-brand card partnership fueling the recovery. Technically, the stock is consolidating in an orderly flag above its breakout level and its 200-day moving average — though a thin options market offers little institutional confirmation and elevated jet fuel costs leave it sensitive to a risk-off tape, so a pullback toward support may offer a more favorable entry.
Palo Alto Networks, Inc. (NASDAQ: PANW) — The cybersecurity leader delivered a decisive beat-and-raise quarter, with revenue up 39% and next-generation security annual recurring revenue up 66%, while expanding aggressively into AI through its $4.5 billion Applied Compute acquisition — and it drew the heaviest bullish options flow of any name in our screens. Still, the stock remains below its 50-day moving average with dense overhead supply and momentum only beginning to turn, so a confirmed breakout above recent highs, or a successful retest of support, could set up the next leg higher.

